Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD-218 in Mixed Dyslipidemia
NCT05400317Phase 3Recruiting
- Sponsor
- Addpharma, Inc.
- Start
- Jul 2022
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of AD-218 in mixed dyslipidemia, sponsored by Addpharma, Inc.. Started Jul 2022; status: recruiting.
02
Drugs
AD-218
03
Conditions
mixed dyslipidemia
Beyond the preview
Go deeper on NCT05400317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05400317.